Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Healthequity (DE:2HE)
FRANKFURT:2HE
Healthequity (2HE) Stock Forecast & Price Target
0 Followers
See the Price Targets and Ratings of:
See bloggers sentiment and opinion on 2HE
>2HE Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2HE Stock 12 Months Forecast
Average Price Target
€77.31
▲(12.04% Upside)
| Highest Price Target€84.21 | Average Price Target€77.31 | Lowest Price Target€68.12 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
Raymond James
€85.15
Buy
23.41%
Upside
Reiterated
HealthEquity, Inc (HQY) PT Raised to $90 at Raymond JamesRaymond James analyst C. Gregory Peters raised the price target on HealthEquity, Inc (NASDAQ: HQY) to $90.00 (from $85.00) while maintaining a Outperform rating.
Guggenheim
€88.94
Buy
28.89%
Upside
Reiterated
We believe that the updated rate can prove to be conservative as HQY laps its trough deposit rates. We reiterate our BUY rating and $94 PT and believe it is attractively priced (down more than 25% off its 52-week high vs. S&P 500 -4%). 4Q beat and F24 guidance raise: Two weeks back, we wrote a note (link) that we expected HQY to increase FY24 guidance on its 4Q23 call, and that happened for both revenue and EBITDA (based on the prior implied EBITDA off the margin guide). After a F4Q beat (compared to our estimates and the top end of the company's guidance), HQY raised the bottom and top ends of its FY24 guidance for both revenue and EBITDA. The midpoint of the revenue range is up $7.5M and the EBITDA midpoint is up ~$6M based on the prior margin guide.
Jefferies
€79.47
Buy
15.18%
Upside
Reiterated
representing a mix of traditionally/self-insured and small/medium/large employers. While we appreciate it is only an N of 35, we believe it offers a helpful snapshot of the HSA market. 1. HQY is the HSA provider of choice, ranking just above primary competitors Optum and Fidelity. 2. Majority of responses indicate HSAs have penetrated <80% of employer market, implying ample white space for additional employers to add this benefit.
Goldman Sachs
€72.85
Hold
5.58%
Upside
Upgraded
HealthEquity upgraded to Neutral from Sell at Goldman SachsHealthEquity upgraded to Neutral from Sell at Goldman Sachs
Best Analysts Covering Healthequity
Which Analyst Should I Follow If I Want to Buy DE:2HE and Sell After:
1 Month
3 Months
1 Year
Success Rate
19/25 ratings generated profit
Average Return
+11.35%
reiterated a buy rating 4 months ago
Copying Stephanie Davis's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +11.35% per trade.
2 Years
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
2HE Financial Forecast
2HE Stock Forecast FAQ
What is DE:2HE’s average 12-month price target, according to analysts?
Based on analyst ratings, Healthequity’s 12-month average price target is €77.31.
What is DE:2HE’s upside potential, based on the analysts’ average price target?
Healthequity has 12.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Healthequity a Buy, Sell or Hold?
Healthequity has a conensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Healthequity’s share price target?
The average share price target for Healthequity is €77.31. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €84.21 ,and the lowest forecast is €68.12. The average share price target represents 12.04% Increase from the current price of €69.
The highest analyst share price target is €84.21 ,and the lowest forecast is €68.12. The average share price target represents 12.04% Increase from the current price of €69.
What do analysts say about Healthequity?
Healthequity’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of Healthequity?
To buy shares of DE:2HE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.